Home · Stock · NTRA

NTRA Natera Inc

Which ETFs hold NTRA? Natera Inc is held by 2 funds tracked by ETFpeek.

Held by 2 funds todayData as of 9 Oct 2026
HealthcareDiagnostics & Research
$390.79
+130.9% 1y
$167.9952-week range$437.41
Market cap
$59.1B
3-month
+44.8%
CEO
Mr. Steven Leonard Chapman
Revenue · last 4 qtrs (+37.7% YoY)

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Provider

Currently Held By

ARK
ARKG
ARK Genomic Revolution ETF
Weight in fund4.71%
Shares held246,976
Market value$96.5M
View fund →
ARK
ARKK
ARK Innovation ETF
Weight in fund1.05%
Shares held185,580
Market value$72.5M
View fund →
Not held by the selected provider.
last 90 days
Net flow (90d):−$24.4M (1 without value)·1 BUY / 76 SELL·score ≥ 40
DatePersonActionPlanSharesValueScore i
1 Oct 2026
Solomon Moshkevich
President of Clinical Diagnostics
SELLUnknown1,846$766K50
1 Oct 2026
Steven Leonard Chapman
CEO & Director
SELLUnknown1,273$526K50
23 Sep 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown16,944
8 tranches
$6.6M60
10 Aug 2026
John Fesko
President & Chief Business Officer
SELLUnknown6,517$2.1M90
10 Aug 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown6,000$2.0M90
7 Aug 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown5,111$1.6M90
7 Aug 2026
Matthew Rabinowitz
Co-Founder & Executive Chairman
SELLUnknown2,000$642K80
28 Jul 2026
Steven Leonard Chapman
CEO & Director
SELLUnknown3,580$910K80
27 Jul 2026
Steven Leonard Chapman
CEO & Director
SELLUnknown2,190$570K80
Net flow (90d):−$24.4M (1 without value)·1 BUY / 76 SELL·showing all trades
DatePersonActionPlanSharesValueScore i
1 Oct 2026
Solomon Moshkevich
President of Clinical Diagnostics
SELLUnknown3,000
3 tranches
$1.2M50
1 Oct 2026
Steven Leonard Chapman
CEO & Director
SELLUnknown1,273$526K50
23 Sep 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown18,064
12 tranches
$7.0M60
10 Aug 2026
John Fesko
President & Chief Business Officer
SELLUnknown6,517$2.1M90
10 Aug 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown6,000$2.0M90
7 Aug 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown8,650
8 tranches
$2.7M90
7 Aug 2026
Matthew Rabinowitz
Co-Founder & Executive Chairman
SELLUnknown2,000$642K80
6 Aug 2026
John Fesko
President & Chief Business Officer
BUYVested (RSU)20,000—0
4 Aug 2026
Michael Burkes Brophy
Chief Financial Officer
SELLUnknown478$131K30
3 Aug 2026
John Fesko
President & Chief Business Officer
SELLUnknown295$79K30
3 Aug 2026
Solomon Moshkevich
President of Clinical Diagnostics
SELLUnknown3,410
7 tranches
$906K30
3 Aug 2026
Daniel Rabinowitz
Secretary & Chief Legal Officer
SELLUnknown334$90K30
3 Aug 2026
Steven Leonard Chapman
CEO & Director
SELLUnknown3,076
7 tranches
$819K30
3 Aug 2026
Michael Burkes Brophy
Chief Financial Officer
SELLUnknown317$85K30
3 Aug 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown109$29K30
3 Aug 2026
Matthew Rabinowitz
Co-Founder & Executive Chairman
SELLUnknown731$196K30
29 Jul 2026
Michael Burkes Brophy
Chief Financial Officer
SELLUnknown1,863$465K30
28 Jul 2026
Steven Leonard Chapman
CEO & Director
SELLUnknown3,580$910K80
28 Jul 2026
John Fesko
President & Chief Business Officer
SELLUnknown931$237K30
28 Jul 2026
Solomon Moshkevich
President of Clinical Diagnostics
SELLUnknown1,204$306K30
28 Jul 2026
Daniel Rabinowitz
Secretary & Chief Legal Officer
SELLUnknown1,003$255K30
28 Jul 2026
Michael Burkes Brophy
Chief Financial Officer
SELLUnknown2,419
3 tranches
$614K30
28 Jul 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown191$49K30
27 Jul 2026
Steven Leonard Chapman
CEO & Director
SELLUnknown2,190$570K80
27 Jul 2026
John Fesko
President & Chief Business Officer
SELLUnknown782$204K30
27 Jul 2026
Solomon Moshkevich
President of Clinical Diagnostics
SELLUnknown1,010$263K30
27 Jul 2026
Daniel Rabinowitz
Secretary & Chief Legal Officer
SELLUnknown884$230K30
27 Jul 2026
Michael Burkes Brophy
Chief Financial Officer
SELLUnknown782$204K30
27 Jul 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown288$75K30
27 Jul 2026
Matthew Rabinowitz
Co-Founder & Executive Chairman
SELLUnknown1,718$448K30
15 Jul 2026
Rowan E Chapman
Director / Other
SELLUnknown135$37K30
15 Jul 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown1,500
8 tranches
$411K30
13 Jul 2026
Jonathan Sheena
Co-Founder & Director
SELLUnknown2,150
4 tranches
$572K30
Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic
17 trades
DateFundDirectionShares Changed% Δ ETF i% Δ Position i
9 Oct 2026ARKKSELLReduced-19,446-0.13%9.48%
15 Sep 2026ARKKSELLReduced-7,803+0.00%3.69%
18 Aug 2026ARKKSELLReduced-20,309-0.09%8.65%
5 Aug 2026ARKKSELLReduced-3,207-0.05%1.32%
4 Aug 2026ARKKSELLReduced-18,060-0.11%7.02%
31 Jul 2026ARKKSELLReduced-4,485+0.05%1.70%
29 Jul 2026ARKKSELLReduced-6,746-0.10%2.53%
21 Jul 2026ARKKSELLReduced-11,228-0.09%3.99%
17 Jul 2026ARKKSELLReduced-19,373-0.07%6.40%
10 Jul 2026ARKKSELLReduced-21,580-0.07%6.28%
10 Jul 2026ARKGSELLReduced-4,889-0.07%2.00%
9 Jul 2026ARKKSELLReduced-14,051-0.07%4.04%
9 Jul 2026ARKGSELLReduced-2,893-0.09%1.17%
8 Jul 2026ARKKSELLReduced-12,554-0.03%3.48%
8 Jul 2026ARKGSELLReduced-8,439-0.07%3.28%
16 Jun 2026ARKKSELLReduced-5,845-0.10%1.42%
12 Jun 2026ARKKSELLReduced-25,532-0.07%4.98%
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

More stocks in these funds